Oral anticoagulants (OAC), including vitamin K antagonists (VKAs) and non-VKA oral anticoagulants (NOACs) are recommended to prevent thromboembolic events in patients with atrial fibrillation (AF) and for primary and secondary prevention of venous thromboembolism (VTE). However, OAC use is associated with an increased risk of major bleeding, the most serious of which is intracranial hemorrhage (ICH). 1 In clinical practice, estimating the bleeding risk of an individual patient is beneficial before starting an anticoagulant, 2 particularly to identify and manage modifiable bleeding risk factors. In addition bleeding risk assessment could help to identify those at higher bleeding risk for whom additional measures, such as more regular follow-up visits and good International Normalised Ratio (INR) management (for those on VKAs), providing information and/or practical measures to reduce the falls risk, and informing patients about high-risk activities 1 to reduce bleeding risk 3 could be implemented. Bleeding risk scoring systems have been developed for use in AF and VTE patients to estimate bleeding risk and to help aid treatment decisions. These scores have been tested and validated worldwide in many cohorts of AF [4] [5] [6] [7] [8] [9] and VTE [10] [11] [12] to support physicians in assessing bleeding risks. 13 More recently, the European Society of Cardiology (ESC)
Guidelines on the management of AF summarised bleeding risks (into modifiable, potentially modifiable, non-modifiable and biomarker-based) and encouraged prompt attention to correct modifiable bleeding risks. 14 This review summarises the original derivation and validation studies of these bleeding risk scores for stroke prevention in AF and treatment/prevention of VTE. Table   2 ). All 3 [10] [11] [12] bleeding scores for VTE patients include history or current diagnosis of cancer in their bleeding score, as cancer is shown to increase the risk of thromboembolism. 17, 18 Interestingly the ORBIT 5 score and the score developed by Ruiz-Gimenez et al 11 found almost 60% of their population had anemia, also a known risk factor for bleeding. In most bleeding scores [4] [5] [6] [7] 9 for AF, hypertension was the most prevalent co-morbidity followed by congestive heart failure and diabetes.
Methods
Clinically overt PE was included as a risk factor for bleeding only in the VTE bleeding score by Ruiz-Gimenez et al. 11 The aim of the other 2 VTE scores 10, 12 was to develop a score with the ability to distinguish patients at low, mild or high risk of major bleeding during the first 90 days of OAC therapy. (Table 2) . Almost half of the population in the derivation studies were female and only 3 studies 5, 6, 15 reported ethnicity, which was predominantly White. Five out of 6 [4] [5] [6] [7] 9 studies from the AF cohorts reported hypertension as the most common co-morbid disease present in their population whereas one study from a VTE cohort 10 and the mixed cohort 15 reported kidney disease to be more prevalent in their patient population. score from the previous bleeding score available in AF, while a retrospective study design was used in 1 12 VTE study and 1 mixed population study. 15 Most studies in AF patients had follow-up for at least 1 year except the first score developed by Shiremen et al 9 which followed their patients for the first 90 days following hospital discharge after AF diagnosis. In contrast, bleeding scores derived from VTE cohorts usually followed up patients for 3 months, as the duration of treatment of DVT/PE with warfarin is typically between 3-12 months depending on the type of VTE. 19 All studies derived their risk score using bleeding risk factors from large cohorts of patients ranging from 3456 7 to almost 20,000 9 patients, apart from 2 studies, by Kuijer and Landefield et al. which only included 241 and 556 patients, respectively.
12,15
All bleeding risk scores stratified patients into 3 categories of bleeding risk (low, intermediate and high) except for the HAS-BLED score which initially categorised bleeding risk as high (score ≥3) and lowmoderate risk (0-2) 1 and IMPROVE 10 which categorized scores as ≥7 (increased risk of bleeding) and <7.
These bleeding risk scores showed major bleeding rates ranging from 0.1%-3% in the low risk group and 4.9%-30% in the high risk group in the validation cohorts. (Table 4) In terms of VTE prophylaxis, the most recent bleeding risk score developed to assess bleeding risks is the IMPROVE, 10 and is perhaps the most comprehensive score by including more predictors of major bleeding (10 predictors), compared to the scores by Ruiz-Gimenez et al 11 (6 predictors) and Kuijer et al 12 (3 predictors ).
The earliest bleeding score developed by Landefeld et al 15 in 1989 derived 5 predictive factors of major bleeding in a mixed indication population. One of the original risk factors was AF but this was later removed when the score was validated, as its association with major bleeding was no longer significant in the validation cohort. Diabetes mellitus was substituted instead of AF as a new predictor of major bleeding.
The ability of the bleeding risk scores to predict bleeding risk has been validated both in cohorts to similar to ones where the score was derived (4 studies) 6,7,9,11 and in independent validation cohorts (6 studies). 4, 5, 8, 10, 12, 20 In the validation and comparison study by Hijazi et al, 4 the ABC score statistically outperformed the HAS-BLED and ORBIT scores in predicting major bleeding in both the derivation cohort [0·68 (95% CI 0·66-0·70) vs. 0·61 (0·59-0·63) vs. 0·65 (0·62-0·67), respectively; ABC-bleeding vs.
HAS-BLED p<0·0001 and ABC-bleeding vs. ORBIT p=0·0008] and the external validation cohort [0·71 (95% CI 0·68-0·73) vs. 0·62 (0·59-0·64) for HAS-BLED vs. 0·68 (0·65-0·70) for ORBIT; ABC-bleeding
vs. HAS-BLED p<0·0001 and ABC-bleeding vs. ORBIT p=0·0016]. 4 Although the ABC score performed better than the HAS-BLED and ORBIT scores in this report, the complexity of the algorithm and inclusion of biomarkers which are not routinely performed in daily clinical practice, may make it difficult and more costly, for physicians to apply routinely.
One recent meta-analysis 21 and ATRIA in the AMADEUS trial and demonstrated that the HAS-BLED score performed better than HEMORR 2 HAGES and ATRIA score in predicting any clinically relevant bleeding, with only the HAS-BLED score demonstrating significant improvement for intracranial hemorrhage. 25 In another ancillary analysis of the same trial, 26 the HAS-BLED score performed better than the ORBIT score in predicting any clinically relevant bleed in a non-oral anticoagulant (idraparinux). 26 More recently the predictive ability of the HAS-BLED score was also investigated in patients receiving NOAC therapy, with rivaroxaban, in a small retrospective case-control study; 27 the HAS-BLED score demonstrated modest diagnostic ability to predict major bleeding events although this was not statistically significant (c statistics=0.68; p=0.07). 27 Analyses have demonstrated that the HAS-BLED score not only performs well in predicting bleeding events in VKA treated patients with AF, it can also be used to predict bleeding events in non-VKA treated patients which is very useful as more AF patients are being treated with NOACs. 
28
In conclusion, balancing individual risk of thromboembolic events and bleeding is complex but maximising the benefit of OAC while minimising bleeding risk, resulting in a net clinical benefit, should be undertaken in all patients receiving OAC. As reviewed here, there are many clinical prediction tools to assess bleeding risk prior to starting OAC for either stroke prevention in AF or treatment of VTE, which should be used in clinical practice to identify and manage modifiable risk factors. 
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 Age≥75     Age≥70  Age≥65   Age ≥60  Age≥50  Biomarkers  Previous/remote bleed         Recent bleed  Anaemia       Renal disease        Liver disease    Hypertension    Myocardial infarction  Diabetes   Malignancy     Stroke    Combined
